Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Ozipco 1% Methylene Blue
Generic Name
Methylene Blue
Active Ingredient
Methylene BlueCategory
Nitrogen Binding Agent [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1 g/100mL | SOLUTION | EXTRACORPOREAL | 86241-003 |
Detailed information about Ozipco 1% Methylene Blue
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Ozipco 1% Methylene Blue, you must consult a qualified healthcare professional.
Methylene Blue is a thiazine dye and nitrogen binding agent primarily used to treat acquired methemoglobinemia. It functions by facilitating the conversion of methemoglobin back to hemoglobin, thereby restoring the blood's essential oxygen-carrying capacity.
For the treatment of acute acquired methemoglobinemia, the standard adult dose is 1 mg/kg to 2 mg/kg of body weight. This is typically administered intravenously as a 1% solution over a period of 5 to 30 minutes. If the methemoglobin levels remain high (above 30%) or if clinical symptoms of hypoxia persist, a repeat dose of 1 mg/kg may be given one hour after the initial dose. It is critical to monitor the patient closely via co-oximetry, as excessive doses of Methylene Blue can actually cause methemoglobinemia or hemolytic anemia (destruction of red blood cells).
For off-label ifosfamide-induced encephalopathy, doses of 50 mg every 4 to 8 hours are commonly cited in clinical literature until symptoms resolve. In vasoplegic syndrome, a bolus of 1.5-2 mg/kg followed by an infusion is sometimes utilized in specialized surgical settings.
In pediatric patients, including neonates, the dosage for methemoglobinemia is similar to the adult dose: 1 mg/kg to 2 mg/kg administered intravenously over 5 to 30 minutes. However, extreme caution is required in neonates and infants. Neonates have lower levels of NADPH-methemoglobin reductase, making them more susceptible to the oxidative stress caused by Methylene Blue. Doses should be precisely calculated based on actual body weight to avoid toxicity.
Since approximately 75% of Methylene Blue is excreted renally, patients with significant kidney dysfunction (estimated GFR < 30 mL/min) may require dose reductions or extended intervals between doses. While specific guidelines are not established, close monitoring for toxicity is mandatory.
Methylene Blue is not extensively metabolized by the liver in a way that requires standard Child-Pugh adjustments; however, since it can impact the biliary system and cause some hepatotoxicity at high doses, caution is advised in patients with severe liver disease.
Older adults often have decreased renal function and a higher prevalence of polypharmacy (taking multiple medications). Dosage should start at the lower end of the range, with careful monitoring of renal function and potential drug interactions, particularly with serotonergic antidepressants.
In most clinical scenarios, Methylene Blue is administered by a healthcare professional in a hospital or clinic setting.
Because Methylene Blue is usually given for acute, emergency conditions in a hospital, missed doses are rare. If you are taking an oral form on a schedule and miss a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.
Signs of Methylene Blue overdose include severe nausea, vomiting, chest pain, shortness of breath, tremors, and a paradoxical increase in methemoglobinemia. Large doses (typically > 7 mg/kg) can cause significant hemolysis (red blood cell breakdown), particularly in patients with G6PD deficiency. In the event of an overdose, emergency measures include stopping the infusion, providing supportive care (such as blood transfusions if hemolysis is severe), and monitoring for cardiac arrhythmias.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without direct medical guidance, as methemoglobinemia can be fatal if undertreated.
Methylene Blue is known for several highly visible but often benign side effects due to its properties as a dye.
> Warning: Stop taking Methylene Blue and call your doctor immediately if you experience any of these symptoms. These may indicate a life-threatening reaction.
Methylene Blue is rarely used for long-term therapy. However, in cases where it is used chronically (e.g., for certain metabolic disorders), potential long-term effects include chronic anemia due to low-level hemolysis and potential bladder irritation from the constant presence of the dye in the urine. There is limited data on the carcinogenic potential of long-term Methylene Blue use in humans, though animal studies have raised some concerns at very high, chronic doses.
While Methylene Blue does not carry a traditional 'Black Box Warning' for all indications, the FDA has issued strong Safety Communications regarding the risk of Serotonin Syndrome. The warning states that Methylene Blue should not be administered to patients receiving serotonergic drugs (such as Prozac, Zoloft, or Effexor) unless the treatment for methemoglobinemia is urgent and life-saving. In such cases, the serotonergic drug must be stopped immediately, and the patient must be monitored for CNS toxicity for two weeks or until 24 hours after the last dose of Methylene Blue.
Report any unusual symptoms, especially changes in mood or heart rhythm, to your healthcare provider immediately.
Methylene Blue is a high-alert medication that requires careful clinical oversight. The most critical safety concern is its potential to cause Serotonin Syndrome when combined with other serotonergic agents. Additionally, Methylene Blue is a potent oxidant at high doses and a reductant at low doses, meaning that improper dosing can worsen a patient's clinical status. Patients must be screened for G6PD deficiency whenever possible before administration, as the drug can cause fatal hemolysis in these individuals.
As of 2024, there is no formal 'Black Box' on the ProvayBlue label, but there are Major Warnings regarding Serotonin Syndrome. The FDA warns that Methylene Blue is a potent monoamine oxidase inhibitor (MAOI). When administered to patients taking Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), or other serotonergic drugs, it can lead to toxic levels of serotonin in the brain, resulting in confusion, coma, and death.
Patients receiving Methylene Blue require intensive monitoring, typically in an emergency department or intensive care unit (ICU) setting:
Methylene Blue may cause dizziness, blurred vision, and confusion. Patients should not drive or operate heavy machinery for at least 24 hours after receiving an injection, or until they are certain the effects of the drug have completely worn off.
Alcohol should be avoided while Methylene Blue is in the system. Alcohol can increase the sedative effects of the drug and may increase the risk of gastrointestinal irritation. Furthermore, the combined effect on the central nervous system could mask signs of serotonin toxicity.
For acute methemoglobinemia, Methylene Blue is usually a one-time or short-term treatment. There is no withdrawal syndrome associated with stopping the drug. However, if used for off-label chronic conditions, it should be tapered under medical supervision to ensure the underlying condition does not rebound.
> Important: Discuss all your medical conditions, especially any history of anemia or depression, with your healthcare provider before starting Methylene Blue.
For each major interaction, the mechanism is usually related to MAO inhibition or CYP enzyme inhibition. The clinical consequence is typically increased drug toxicity (e.g., serotonin toxicity or reduced clearance of other meds). Management involves stopping the offending agent and providing supportive care.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for depression or pain.
Patients who are allergic to other thiazine dyes (sometimes used in industrial settings or as biological stains) may experience cross-reactivity with Methylene Blue. There is no documented cross-sensitivity between Methylene Blue and sulfonamides (sulfa drugs), despite some older clinical myths suggesting a link.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'favism' (G6PD deficiency symptoms after eating fava beans), before prescribing Methylene Blue.
Methylene Blue is classified as Pregnancy Category X for certain uses (like intra-amniotic injection) and Category C or D for intravenous use depending on the jurisdiction. According to the FDA, Methylene Blue can cause fetal harm when administered to a pregnant woman. It has been associated with fetal intestinal atresia (a blockage of the bowel) and other malformations when used during pregnancy. It should only be used during pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus, such as in life-threatening methemoglobinemia.
It is not known whether Methylene Blue is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (such as hemolysis or hyperbilirubinemia), breastfeeding should be discontinued for up to 8 days after treatment with Methylene Blue. This timeframe allows for the drug and its metabolites to be fully cleared from the mother's system.
Methylene Blue is FDA-approved for use in pediatric patients, including neonates, for the treatment of methemoglobinemia. However, extreme caution is required. Neonates are particularly sensitive to oxidative stress. There is a risk of inducing hemolytic anemia and hyperbilirubinemia (jaundice) in this population. Dosing must be precisely calculated based on weight (1-2 mg/kg).
Clinical studies of Methylene Blue did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, because the drug is substantially excreted by the kidney, the risk of adverse reactions may be greater in patients with impaired renal function. Since elderly patients are more likely to have decreased renal function, dose selection should be cautious, and renal function should be monitored.
In patients with mild to moderate renal impairment, Methylene Blue should be used with caution. In severe renal impairment (CrCl < 30 mL/min), the drug's half-life is significantly prolonged. This increases the risk of both CNS toxicity and paradoxical methemoglobinemia. Dose reductions are often necessary.
Methylene Blue has not been formally studied in patients with hepatic impairment. However, since it is a dye that can be processed by the liver and excreted in bile, patients with biliary obstruction or severe cirrhosis should be monitored for signs of increased systemic toxicity and localized liver injury.
> Important: Special populations require individualized medical assessment and often require lower starting doses and more frequent lab monitoring.
Methylene Blue acts as a low-potential redox compound. Its primary clinical utility in methemoglobinemia stems from its ability to serve as an electron carrier. Inside the erythrocyte, Methylene Blue is reduced to leucomethylene blue by the enzyme NADPH-methemoglobin reductase. Leucomethylene blue then non-enzymatically reduces methemoglobin (Fe3+) back to functional hemoglobin (Fe2+).
At the cardiovascular level, Methylene Blue inhibits the enzyme soluble guanylate cyclase (sGC). By doing so, it prevents the conversion of GTP to cGMP. Since cGMP is a potent mediator of smooth muscle relaxation (vasodilation), inhibiting its production leads to increased vascular tone and blood pressure. This is the basis for its use in refractory shock states.
The onset of action for reducing methemoglobin levels is rapid, typically occurring within 30 to 60 minutes of intravenous administration. The duration of effect is variable but generally lasts for several hours, though methemoglobin levels can 'rebound' if the offending toxin is still present in the patient's system. Methylene Blue also has mild antiseptic and antimalarial properties, though it is no longer the standard of care for those indications.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (IV); 70-80% (Oral) |
| Protein Binding | 71% - 77% |
| Half-life | 5 - 24 hours |
| Tmax | 0.5 - 2 hours (Oral) |
| Metabolism | Reduced to leucomethylene blue (non-CYP) |
| Excretion | Renal (~75%), Fecal (minor) |
Methylene Blue is classified as a Nitrogen Binding Agent [EPC] and a Thiazine Dye. It is therapeutically categorized as an antidote and a redox agent. Related medications in the broader 'antidote' class include sodium thiosulfate (for cyanide) and acetylcysteine (for acetaminophen), though Methylene Blue's specific mechanism is unique to the treatment of methemoglobinemia.
Common questions about Ozipco 1% Methylene Blue
Methylene Blue is primarily used as an FDA-approved treatment for acquired methemoglobinemia, a serious blood disorder where oxygen cannot be effectively released to the body's tissues. It works by converting an abnormal form of hemoglobin back into a functional state that can carry oxygen. Additionally, it is used off-label in hospitals to treat ifosfamide-induced encephalopathy and certain types of severe low blood pressure during surgery. It is also sometimes used as a diagnostic dye to identify tissues or leaks during surgical procedures. Because of its potent effects on the brain and blood, it must only be administered under strict medical supervision.
The most common and expected side effect of Methylene Blue is the discoloration of urine and stool, which typically turn a blue or green color. Patients also frequently report pain in the limb where the IV was administered, as well as headaches, dizziness, and increased sweating. Some individuals may experience nausea, vomiting, or a transient increase in blood pressure shortly after the infusion. While these are often mild, they can be distressing if the patient is not forewarned. Most of these effects disappear within 24 to 48 hours as the drug is cleared from the body.
It is strongly advised to avoid alcohol while being treated with Methylene Blue. Alcohol can worsen the dizziness and confusion that often accompany Methylene Blue treatment, potentially leading to increased safety risks. Furthermore, because Methylene Blue acts as a mild monoamine oxidase inhibitor (MAOI), combining it with alcohol—especially certain types like draft beer or red wine which contain tyramine—could theoretically lead to a dangerous spike in blood pressure. Always wait until the drug has completely cleared your system, usually at least 48 hours after the last dose, before consuming alcohol. Consult your doctor for specific guidance based on your recovery.
Methylene Blue is generally considered unsafe during pregnancy and should only be used if the mother's life is at risk and no other treatments are available. It has been linked to fetal abnormalities, specifically intestinal atresia, when used in certain medical procedures during pregnancy. Animal studies have also shown evidence of fetal harm and potential miscarriage. If you are pregnant or planning to become pregnant, you must inform your healthcare provider immediately before receiving this medication. The risks to the developing fetus are significant enough that alternative treatments for methemoglobinemia are usually preferred if the situation is not an absolute emergency.
When administered intravenously for methemoglobinemia, Methylene Blue works very quickly, with initial reductions in methemoglobin levels often seen within 30 minutes. Most patients will show a significant improvement in their oxygen saturation and a reduction in 'blue' skin color (cyanosis) within one hour of the first dose. If the condition was caused by a long-acting toxin, a second dose might be required an hour later. Your medical team will monitor your blood levels continuously to ensure the drug is working effectively. The rapid onset is critical because methemoglobinemia can quickly lead to organ damage if not reversed.
Since Methylene Blue is typically given as a short-term treatment in an emergency or hospital setting, there is no risk of 'withdrawal' in the traditional sense. Once the methemoglobinemia is resolved, the medication is simply stopped. However, it is vital that the drug is not stopped prematurely if the underlying cause of the blood disorder (such as a specific chemical exposure) is still present in your body. Stopping too early could result in a 'rebound' of the condition, where methemoglobin levels rise again. Your doctor will use blood tests to determine the exact time it is safe to discontinue the medication.
If you are receiving Methylene Blue in a hospital, your nurses and doctors will manage the schedule, making a missed dose highly unlikely. If you are taking an oral form of Methylene Blue at home for a specific condition and miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and continue with your regular timing. Never take two doses at once to make up for a missed one, as this increases the risk of serious side effects like hemolytic anemia. Contact your healthcare provider if you miss more than one dose.
There is no clinical evidence to suggest that Methylene Blue causes weight gain. Because it is almost always used as a short-term or emergency treatment, it does not have the metabolic or hormonal effects typically associated with medications that cause weight changes. If you notice sudden swelling or weight gain after treatment, it is more likely related to the intravenous fluids given in the hospital or an underlying heart or kidney issue rather than the Methylene Blue itself. Always report sudden weight changes or swelling in your legs to your doctor immediately, as this may require medical evaluation.
Methylene Blue has many serious drug interactions, particularly with antidepressants like SSRIs (Prozac, Zoloft) and SNRIs (Effexor). Taking these together can cause a life-threatening condition called Serotonin Syndrome. It also interacts with certain pain medications like tramadol and tapentadol. Because Methylene Blue affects liver enzymes (CYP450), it can change how your body processes many other drugs, including blood thinners and heart medications. You must provide your healthcare team with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking before receiving Methylene Blue.
Yes, Methylene Blue is available as a generic medication, although it is often referred to by its chemical name, methylthioninium chloride. In the United States, the brand name ProvayBlue is a common FDA-approved version used in hospitals. Generic versions are typically much more cost-effective and are held to the same safety and efficacy standards as the brand-name drug. However, because it is primarily an institutional drug used in hospitals, patients do not usually 'shop' for it at a retail pharmacy. Your hospital's formulary will determine which version of the medication you receive during your treatment.
Other drugs with the same active ingredient (Methylene Blue)